Boehringer Ingelheim Corporate NewsBoehringer Ingelheim Corporate Newshttp://www.boehringer-ingelheim.com/rss/press/rssfeed.xml09 Feb 2012 23:47:07 +0100Boehringer Ingelheim, GWT and the TU Dresden sign diabetes research collaboration03 Feb 2012 00:00:00 +0100http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2012/03_february_2012collaboration.htmlhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2012/03_february_2012collaboration.htmlFDA approves Jentadueto™ (linagliptin/metformin hydrochloride) tablets for the treatment of adults with Type 2 Diabetes31 Jan 2012 00:00:00 +0100http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2012/31_january_2012_diabetes.htmlNew treatment combines DPP-4 inhibitor, linagliptin (the active ingredient in Trajenta™ [linagliptin] tablets), and metformin in a single tablet, taken twice-daily, to lower blood glucose in adults with Type 2 Diabetes - For Non-U.S. and Non-UK Mediahttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2012/31_january_2012_diabetes.htmlBoehringer Ingelheim launches ‘Lean-to-Clinic’ program for fast drug product supply26 Jan 2012 00:00:00 +0100http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2012/26_january_2012_lean-to-clinic.htmlhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2012/26_january_2012_lean-to-clinic.htmlBoehringer Ingelheim Moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib*26 Jan 2012 00:00:00 +0100http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2012/26_january_2012_oncology.htmlTwo studies investigating afatinib* in patients with locally advanced or recurrent/metastatic head and neck cancer are open for recruitment. - FOR NON-US MEDIA ONLYhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2012/26_january_2012_oncology.htmlBoehringer Ingelheim significantly expands its supply center for China14 Dec 2011 00:00:00 +0100http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/14_december_2011centerforchina.htmlhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/14_december_2011centerforchina.htmlBoehringer Ingelheim completes patient entry for Phase III trial programme in Hepatitis C09 Dec 2011 00:00:00 +0100http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/09_december_2011hepc.html- For media outside the U.S.http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/09_december_2011hepc.htmlLinagliptin demonstrates meaningful improvement in glycaemic control in initial combination therapy with metformin08 Dec 2011 00:00:00 +0100http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/08_december_2011linagliptin.htmlAdditional data on linagliptin monotherapy shows durable glucose control with a low risk of hypoglycaemia   - EX US, UK and UAE Medical Media Only. Under embargo until 08 Dec, 10 am CEThttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/08_december_2011linagliptin.htmlWinners of the Making More Health Competition Bring Fresh Innovation to Solving Problems in Health07 Dec 2011 00:00:00 +0100http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/07_december_2011ashokammh.htmlhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/07_december_2011ashokammh.htmlBoehringer Ingelheim and AVEO Pharmaceuticals announce manufacturing agreement for ficlatuzumab01 Dec 2011 00:00:00 +0100http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/01_december_2011aveo.htmlhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/01_december_2011aveo.htmlPradaxa® awarded Prix Galien for most innovative product in Canada23 Nov 2011 00:00:00 +0100http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/23_november_2011dabigatran.html- For NON-US, Non-Canada and NON-UK Healthcare Media Onlyhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/23_november_2011dabigatran.htmlBoehringer Ingelheim race to the finish line in support of World Diabetes Day17 Nov 2011 00:00:00 +0100http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/17_november_2011worlddiabetesday.htmlKilometres converted into 15,000 Euro donation for IDF 'Life for a Child' Programme as Boehringer Ingelheim undertakes week of activities to support World Diabetes Day - EX US and UK.http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/17_november_2011worlddiabetesday.htmlNew RE-LY® sub-analyses demonstrate safety and efficacy of Pradaxa® (dabigatran etexilate) in patients with heart failure & those undergoing surgery14 Nov 2011 00:00:00 +0100http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/14_november_2011dabigatran.html• Pradaxa® 150mg bid reduced the risk of stroke in atrial fibrillation patients with symptomatic heart failure (sHF) compared to well-controlled warfarin 1 • Rates of major bleeding in patients with sHF taking Pradaxa® are consistent with results seen in the RE-LY® trial, with significantly lower rates of intracranial bleeds 1-3 • Pradaxa® was not associated with an increased risk of peri-operative bleeding compared to well-controlled warfarin, even among patients having emergency or major surgery. 4 - For NON-US, NON-Canada and NON-UK Healthcare Media Onlyhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/14_november_2011dabigatran.htmlThirteen Finalists Chosen for Boehringer Ingelheim and Ashoka Changemakers "Making More Health" Competition09 Nov 2011 00:00:00 +0100http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/09_november_2011ashokachangemakers.htmlhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/09_november_2011ashokachangemakers.htmlBI 201335 demonstrates potential to shorten HCV treatment duration while achieving high sustained virological response rates in difficult to treat patients08 Nov 2011 00:00:00 +0100http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/08_november_2011hcv.htmlData from SILEN-C1 and SILEN-C3 trial presented at AASLD - For media outside of the U.S.A onlyhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/08_november_2011hcv.htmlHepatitis C: Interferon-free combination of BI 201335 plus BI 207127 and ribavirin shows up to 76% of patients achieve a virological response at week 12, and 59% achieve SVR12 with 16 weeks treatment07 Nov 2011 00:00:00 +0100http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/07_november_2011hepc.htmlData from pre-specified interim analysis of Phase IIb SOUND-C21 trial with Boehringer Ingelheim’s two investigational HCV direct-acting antivirals presented at AASLD - For media outside of the U.S.A. onlyhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/07_november_2011hepc.htmlBoehringer Ingelheim gains approval of extended 4.5 hour time-window for Actilyse® in acute ischaemic stroke for majority of EU countries*04 Nov 2011 00:00:00 +0100http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/04_november_2011_alteplase.html• Until today Actilyse® (Alteplase, rt-PA) is the only approved treatment option for patients with acute ischaemic stroke • Early thrombolysis is and stays important and can increase the benefit for acute ischaemic stroke patients - For non-UK and non-US mediahttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/04_november_2011_alteplase.htmlNICE issues Final Appraisal Determination (FAD) with unrestricted recommendation for Pradaxa® (dabigatran etexilate) for patients with non-valvular atrial fibrillation01 Nov 2011 00:00:00 +0100http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/01_november_2011dabigatran.htmlThe FAD states that Pradaxa® “is a cost-effective use of National Health Service (NHS) resources when used within its licensed indication.” - For NON-US, UK & Canada Media Onlyhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/01_november_2011dabigatran.htmlBoehringer Ingelheim implements additional guidance supporting appropriate use of Pradaxa® (dabigatran etexilate) in Europe27 Oct 2011 00:00:00 +0200http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/27_october_2011_dabigatran.html- For European Health Media Onlyhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/27_october_2011_dabigatran.htmlBoehringer Ingelheim and Gilead sign license agreement for novel HIV non-catalytic integrase inhibitors06 Oct 2011 00:00:00 +0200http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/06_october_2011_gilead.htmlCompounds Represent New Class of Antiretroviralhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/06_october_2011_gilead.htmlBIBF 1120* in patients with metastatic colorectal cancer as effective as bevacizumab with less serious adverse events27 Sep 2011 00:00:00 +0200http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/27_september_2011oncology1.htmlResults from a Phase I/II study among the few to have been selected for presentation in the Presidential Session at the 2011 European Multidisciplinary Cancer Congress (EMCC). - FOR NON-US MEDIA ONLYhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/27_september_2011oncology1.htmlEuropean Respiratory Society (ERS) Awards Annual COPD Research Prize27 Sep 2011 00:00:00 +0200http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/27_september_2011copd.htmlCOPD Research Award sponsored by Boehringer Ingelheim in its 11th consecutive yearhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/27_september_2011copd.htmlBoehringer Ingelheim expands its Business with Biosimilars26 Sep 2011 00:00:00 +0200http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/26_september_2011biosimilars.htmlhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/26_september_2011biosimilars.htmlNew Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis22 Sep 2011 00:00:00 +0200http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/22_september_2011ipf.htmlResults from Phase II TOMORROW trial with BIBF 1120* also presented at European Respiratory Society (ERS) 2011 Annual Congress - For NON-U.S Health Media Onlyhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/22_september_2011ipf.htmlViramune® (nevirapine) prolonged-release once-daily formulation for the treatment of HIV-1 infection receives approval in the EU21 Sep 2011 00:00:00 +0200http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/21_september_2011nevirapine.html- For non-US healthcare mediahttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/21_september_2011nevirapine.htmlBoehringer Ingelheim enrols first patient in Phase III program for new once-daily fixed-dose combination of tiotropium plus olodaterol in COPD21 Sep 2011 00:00:00 +0200http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/21_september_2011olodaterol.html- For Media outside the U.S. and Canadahttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/21_september_2011olodaterol.htmlNew data for once-daily linagliptin show durable efficacy over two years16 Sep 2011 00:00:00 +0200http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/16_september_2011_linagliptin.htmlLinagliptin studies also demonstrate meaningful glycaemic control in patients whose blood glucose is inadequately controlled by metformin alone - For Medical Media outside the US and UK only.http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/16_september_2011_linagliptin.htmlBoehringer Ingelheim and EFSD collaborate to support diabetes research in Europe13 Sep 2011 00:00:00 +0200http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/13_september_2011diabetes.htmlPartnership will establish €2.5 million research grant over the next three years - For NON-UK and NON-US / Medical Media only.http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/13_september_2011diabetes.htmlBoehringer Ingelheim wins Frost & Sullivan Award for Biopharmaceutical Contract Manufacturing07 Sep 2011 00:00:00 +0200http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/07_september_2011frostsullivanaward.htmlhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/07_september_2011frostsullivanaward.html€1 million awarded to winning projects which aim to prevent atrial fibrillation-related stroke29 Aug 2011 00:00:00 +0200http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/29_august_2011_1mission1million.html- With the support of actress Jane Seymour, over two million public votes generated - Global disease awareness initiative, 1 Mission 1 Million – Getting to the Heart of Stroke, launches 32 projects from around the world - For non-UK and non-US mediahttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/29_august_2011_1mission1million.htmlBoehringer Ingelheim Broadens its Breast Cancer Trial Programme for Afatinib*29 Aug 2011 00:00:00 +0200http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/29_august_2011_oncology.htmlTwo phase II studies investigating afatinib* in erbB2 (HER2)-overexpressing, metastatic or inflammatory breast cancer are open for recruitment - FOR NON-US MEDIA ONLYhttp://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/29_august_2011_oncology.html